Evidence map›Paper›PMID 31965362›Full record

ArticleEsophagus : official journal of the Japan Esophageal Society2020

Therapeutic results of proton beam therapy with concurrent chemotherapy for cT1 esophageal cancer and salvage endoscopic therapy for local recurrence.

Daiki Sato, Atsushi Motegi, Tomohiro Kadota, Takashi Kojima, Hideaki Bando, Kensuke Shinmura, Keisuke Hori, Yusuke Yoda, Yasuhiro Oono, Sadamoto Zenda and 3 more

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in Esophagus : official journal of the Japan Esophageal Society, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04404491 (The Third Phase of Immunotherapy and Concurrent Chemoradiotherapy in Patients With Esophageal Cancer Recurrence Was Compared With the Clinical Comparison), which is not on this map. Cited by 6 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 2 pooled it
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04404491 phase3unknown statusnot on this map

The Third Phase of Immunotherapy and Concurrent Chemoradiotherapy in Patients With Esophageal Cancer Recurrence Was Compared With the Clinical Comparison

TypeinterventionalSponsorThe First Affiliated Hospital of Henan University of Science and TechnologyRan2020 to 2023Enrolled240ConditionsEsophageal Malignant Neoplasm, Local RecurrenceArmsProcedural death 1, Capecitabine, Radiotherapy, Placebo
3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 2 syntheses or guidelines pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Current status and application of proton therapy for esophageal cancer.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2021
    Review
  5. Review of clinical results of charged-particle therapy for esophageal cancer.Esophagus : official journal of the Japan Esophageal Society · 2021
    Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Daiki SatoDepartment of Gastroenterology and Endoscopy, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa, 277-8577, Japan.
Atsushi MotegiDivision of Radiation Oncology and Particle Therapy, National Cancer Center Hospital East, Kashiwa, Japan.
Tomohiro KadotaDepartment of Gastroenterology and Endoscopy, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa, 277-8577, Japan.
Takashi KojimaDepartment of Gastroenterology and Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Hideaki BandoDepartment of Gastroenterology and Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Kensuke ShinmuraDepartment of Gastroenterology and Endoscopy, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa, 277-8577, Japan.
Keisuke HoriDepartment of Gastroenterology and Endoscopy, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa, 277-8577, Japan.
Yusuke YodaDepartment of Gastroenterology and Endoscopy, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa, 277-8577, Japan.
Yasuhiro OonoDepartment of Gastroenterology and Endoscopy, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa, 277-8577, Japan.
Sadamoto ZendaDivision of Radiation Oncology and Particle Therapy, National Cancer Center Hospital East, Kashiwa, Japan.
Hiroaki IkematsuDepartment of Gastroenterology and Endoscopy, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa, 277-8577, Japan.
Tetsuo AkimotoCourse of Advanced Clinical Research of Cancer, Juntendo University Graduate School of Medicine, Bunkyo-ku, Tokyo, 113-8421, Japan.
Tomonori YanoDepartment of Gastroenterology and Endoscopy, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa, 277-8577, Japan. toyano@east.ncc.go.jp.
National Cancer Center Hospital East · JPJuntendo University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundProton beam therapy (PBT) with concurrent chemotherapy is promising for esophageal squamous cell carcinoma (ESCC). The aim of study was to evaluate the outcome of concurrent chemo-proton therapy (CCPT), i.e., PBT with concurrent chemotherapy for cT1 ESCC and the salvage endoscopic therapy for local recurrence.

methodsPatients with clinical T1 ESCC who underwent CCPT (60 GyE) between April 2013 and April 2017 at the National Cancer Center Hospital East were investigated. The efficacy of CCPT at the primary site was evaluated via endoscopy; primary complete response (CR) was defined as disappearance of the tumor lesion/ulcer and absence of cancer cells on biopsy. Endoscopic evaluation was performed with the same protocol of conventional chemoradiotherapy. Local recurrence after CCPT was treated with endoscopic resection for cT1a and with esophagectomy or photodynamic therapy for cT1b+.

resultsOf the 44 patients (median age, 70 years) that underwent CCPT, 43 patients (98%) achieved primary CR. Among the 44 patients, the 3-year overall survival rate was 95.2%. Five patients (11%) developed local recurrence without regional lymph node or distant metastasis and received endoscopic resection or photodynamic therapy. All five patients were alive with no recurrence after a median 23 months.

conclusionsThe results suggest that CCPT is an effective treatment for cT1 ESCC and careful endoscopic follow-up allows preferable local control with salvage endoscopic treatment.

Indexed as

AdultAgedBiopsyChemoradiotherapyCombined Modality TherapyEndoscopyEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaEsophagectomyFemaleFollow-Up StudiesHumansJapanMaleMiddle AgedNeoplasm Recurrence, LocalDiagnostic imagingEndoscopic resectionEndoscopyUpper gastrointestinal tract

Identifiers

PMID31965362
OpenAlexW3002593477

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.